On-Demand Webinar
Advancing Drug-Drug Interaction Predictions: Utilizing TruVivo®, an All-Human 2D+ Hepatic System
Abstract
Accurate prediction of drug-drug interactions (DDIs) remains a cornerstone in developing safe and effective therapeutics. Traditional in vitro models, particularly hepatocyte monocultures, often fall short in reliably forecasting the induction of drug-metabolizing enzymes and transporters beyond CYP3A, such as CYP2C isoforms, UDP-glucuronosyltransferases (UGTs), and P-glycoprotein (P-gp). This limitation poses challenges in assessing the clinical risk associated with new chemical entities, especially when complex interactions like simultaneous induction and inhibition occur.
This webinar introduces TruVivo®, a novel all-human 2D+ hepatic system comprising hepatocytes, stromal, and endothelial cells. We will explore how TruVivo addresses the shortcomings of traditional models by providing consistent and well-defined induction responses across multiple enzymes and transporters. Key discussion points will include:
- Validation of TruVivo for predicting induction of CYP2C8, CYP2C9, CYP2C19, UGT1A4, CYP3A4, and P-gp.
- Application of TruVivo in delineating complex DDIs involving co-inducers and inhibitors.
- Case studies demonstrating the platform's utility in in situ DDI experiments using clinically relevant drug concentrations.
Attendees will gain insights into how TruVivo enhances the predictive accuracy of DDI assessments, potentially reducing the need for extensive clinical interaction studies and accelerating the drug development process.
Speaker
Diane Ramsden is Senior Director and Head of DMPK at Korro Bio, where she leads preclinical development for RNA editing therapeutics. She brings over 20 years of pharmaceutical industry experience, with prior leadership roles at AstraZeneca and Takeda, supporting drug development across diverse modalities including small molecules, PROTACs, mAbs, ADCs, RNAi, and microbiome-based therapies. Her work spans therapeutic areas such as oncology, GI, neuroscience, cardiometabolic, respiratory, and rare diseases.
She holds three patents, has authored over 75 scientific publications, and delivered more than 30 invited talks. She actively contributes to industry consortia advancing in vitro DDI prediction, serves on the editorial board of Drug Metabolism and Disposition, and is part of the PBSS Boston scientific committee. Her research focuses on the mechanistic understanding of therapeutic disposition using in vitro and in vivo models.